Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPRICA
2024-515584-56-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of benzoyl peroxide in Cutibacterium acnes infection and periprosthetic joint infection (PJI) (2 arms), sponsored by CHU de Nantes. Primary endpoint: Primary: Number of patients in each group with a positive Cutibacterium acnes sample at the dermis. Planned start Oct 2024; status: authorised.
02
Drugs
benzoyl peroxide
03
Conditions
Cutibacterium acnes infectionperiprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2024-515584-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515584-56-00.